Research programme: dual adenosine A2A/A1 receptor antagonists - Johnson & Johnson

Drug Profile

Research programme: dual adenosine A2A/A1 receptor antagonists - Johnson & Johnson

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Class 3-ring heterocyclic compounds; Indenes; Pyrimidines; Small molecules
  • Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
  • 26 Aug 2010 Preclinical trials in Parkinson's disease in USA (PO)
  • 26 Aug 2010 Pharmacodynamics data from preclinical trials presented at the 240th National Meeting of the American Chemical Society (ACS-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top